Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.058
Buy
RSI(14)
54.431
Neutral
STOCH(KDJ)(9,3,3)
54.383
Sell
ATR(14)
0.217
High Vlolatility
CCI(14)
37.595
Neutral
Williams %R
41.772
Buy
TRIX(12,20)
0.626
Sell
StochRSI(14)
0.000
Sell
Search
Genelux Corp
GNLXAdd to Watchlist
2.920USD
-0.120-3.95%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
130.93MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Genelux Corp
Currency: USD Updated: 2026-05-15Key Insights
Genelux Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 178 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.50.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Genelux Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Genelux Corp Highlights
StrengthsRisks
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Growing
The company is in a growing phase, with the latest annual income totaling USD 8.00K.
Fairly Valued
The company’s latest PE is -3.43, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 13.88M shares, increasing 22.23% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 23.10K shares of this stock.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
17.500
Target Price
+475.66%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Genelux Corp is 6.63, ranking 218 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.07
Operational Efficiency
2.69
Growth Potential
6.36
Shareholder Returns
7.03
Genelux Corp's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Genelux Corp is 6.02, ranking 330 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.43, which is -49.87% below the recent high of -1.72 and -1474.37% above the recent low of -53.93.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 178/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Genelux Corp is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 18.00, with a high of 31.00 and a low of 10.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
17.500
Target Price
+475.66%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Genelux Corp
GNLX
6
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Genelux Corp is 4.30, ranking 348 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.29 and the support level at 2.50, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.004
Sell
MA10
2.945
Sell
MA20
2.762
Buy
MA50
2.671
Buy
MA100
2.839
Buy
MA200
3.786
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Genelux Corp is 1.61, ranking 286 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.52. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Genelux Corp’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
Score
Beta vs S&P 500 index
0.51
VaR
--
240-Day Maximum Drawdown
+72.09%
240-Day Volatility
+94.96%
Return
Best Daily Return
60 days
+9.89%
120 days
+9.89%
5 years
--
Worst Daily Return
60 days
-11.64%
120 days
-23.52%
5 years
--
Sharpe Ratio
60 days
+0.99
120 days
-1.04
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+72.09%
3 years
+95.23%
5 years
--
Return-to-Drawdown Ratio
240 days
+0.27
3 years
-0.32
5 years
--
Skewness
240 days
-0.64
3 years
-0.23
5 years
--
Volatility
Realised Volatility
240 days
+94.96%
5 years
--
Standardised True Range
240 days
+10.73%
5 years
--
Downside Risk-Adjusted Return
120 days
-119.14%
240 days
-119.14%
Maximum Daily Upside Volatility
60 days
+53.25%
Maximum Daily Downside Volatility
60 days
+51.25%
Liquidity
Average Turnover Rate
60 days
+0.50%
120 days
+0.58%
5 years
--
Turnover Deviation
20 days
-17.79%
60 days
-8.27%
120 days
+5.34%
Peer Comparison
Biotechnology & Medical Research
Genelux Corp
GNLX
5.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
